Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cingulate Inc ( (CING) ) has shared an update.
On January 12, 2026, Cingulate Inc. increased the maximum aggregate offering price of common stock that can be issued under its at-the-market offering agreement with H.C. Wainwright & Co., LLC, raising the cap from $23.5 million to $31.9 million. As part of this move, the company filed a new prospectus supplement covering an additional $8.84 million of shares, having previously sold approximately $15.1 million of stock under the program, a step that expands its capacity to raise equity capital and may have implications for its financing flexibility and shareholder dilution.
The most recent analyst rating on (CING) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Cingulate Inc stock, see the CING Stock Forecast page.
Spark’s Take on CING Stock
According to Spark, TipRanks’ AI Analyst, CING is a Neutral.
The score is held back mainly by weak financial performance (pre-revenue, widening losses, and persistent cash burn). Offsetting this are meaningful positive corporate milestones (FDA NDA acceptance and added financing) and a modestly constructive technical picture, while valuation is difficult to support due to negative earnings and no dividend.
To see Spark’s full report on CING stock, click here.
More about Cingulate Inc
Average Trading Volume: 174,350
Technical Sentiment Signal: Buy
Current Market Cap: $36.93M
Find detailed analytics on CING stock on TipRanks’ Stock Analysis page.